• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Athira Pharma Inc (NQ: ATHA )

    0.4281 -0.0210 (-4.68%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Athira Pharma Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
    First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming June Conferences
    Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming May Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
    Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and... 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Sidoti Events, LLC's Virtual December Small-Cap Conference
    Via ACCESSWIRE
    These biotechs targeting multiple neurodegenerative diseases
    A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
    Via MarketBeat
    Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
    Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
    Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS) 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
    Data presented at Society for Neuroscience Annual Meeting 2023 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Jefferies London Healthcare Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Participate in Upcoming October Conferences
    From Athira Pharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.